BG64471B1 - Е-2-[4-(4-хлоро-1,2-дифенил-бут-1-енил) фенокси]-етанол и негови фармацевтични състави - Google Patents

Е-2-[4-(4-хлоро-1,2-дифенил-бут-1-енил) фенокси]-етанол и негови фармацевтични състави Download PDF

Info

Publication number: BG64471B1
Authority: BG; Bulgaria
Prior art keywords: ethanol; phenoxy; chloro; enyl; diphenyl
Prior art date: 1998-02-19

Application number

BG104713A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG104713A (bg

Inventor

Marja-Liisa Soedervall

Arja Kalapudas

Antti Vitanen

Eero Maentylae

Original Assignee

Orion Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-19

Filing date

2000-08-28

Publication date

2005-04-30

2000-08-28 Application filed by Orion Corporation filed Critical Orion Corporation

2001-03-30 Publication of BG104713A publication Critical patent/BG104713A/xx

2005-04-30 Publication of BG64471B1 publication Critical patent/BG64471B1/bg

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 5
LUMKNAVTFCDUIE-WCWDXBQESA-N 2-[4-[(e)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]ethanol Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(/CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-WCWDXBQESA-N 0.000 title claims description 12
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 46
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 16
201000001320 Atherosclerosis Diseases 0.000 claims abstract description 6
230000002265 prevention Effects 0.000 claims abstract description 3
150000002148 esters Chemical class 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 14
229940079593 drug Drugs 0.000 claims description 10
238000002657 hormone replacement therapy Methods 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
238000000034 method Methods 0.000 abstract description 9
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract description 6
150000001875 compounds Chemical class 0.000 description 21
235000012000 cholesterol Nutrition 0.000 description 11
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 8
229930182833 estradiol Natural products 0.000 description 8
229960005026 toremifene Drugs 0.000 description 8
XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 8
241000700159 Rattus Species 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
229960005309 estradiol Drugs 0.000 description 7
210000004291 uterus Anatomy 0.000 description 7
230000001833 anti-estrogenic effect Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000001076 estrogenic effect Effects 0.000 description 5
239000000203 mixture Substances 0.000 description 5
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
238000009806 oophorectomy Methods 0.000 description 4
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 4
229960004622 raloxifene Drugs 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
-1 acetic acid Chemical class 0.000 description 3
229940011871 estrogen Drugs 0.000 description 3
239000000262 estrogen Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000007858 starting material Substances 0.000 description 3
XARXSXPYKRGUFO-NVQSTNCTSA-N 1-[(e)-4-chloro-1,2-diphenylbut-1-enyl]-4-(2-phenylmethoxyethoxy)benzene Chemical compound C=1C=CC=CC=1C(/CCCl)=C(C=1C=CC(OCCOCC=2C=CC=CC=2)=CC=1)\C1=CC=CC=C1 XARXSXPYKRGUFO-NVQSTNCTSA-N 0.000 description 2
208000035150 Hypercholesterolemia Diseases 0.000 description 2
102000007330 LDL Lipoproteins Human genes 0.000 description 2
108010007622 LDL Lipoproteins Proteins 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
159000000032 aromatic acids Chemical class 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
229940000406 drug candidate Drugs 0.000 description 2
239000000328 estrogen antagonist Substances 0.000 description 2
239000003777 experimental drug Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
OYXIKBMCUBZEPS-NVQSTNCTSA-N (e)-3,4-diphenyl-4-[4-(2-phenylmethoxyethoxy)phenyl]but-3-en-1-ol Chemical compound C=1C=CC=CC=1C(/CCO)=C(C=1C=CC(OCCOCC=2C=CC=CC=2)=CC=1)\C1=CC=CC=C1 OYXIKBMCUBZEPS-NVQSTNCTSA-N 0.000 description 1
FWOHDAGPWDEWIB-UHFFFAOYSA-N 2-bromoethoxymethylbenzene Chemical compound BrCCOCC1=CC=CC=C1 FWOHDAGPWDEWIB-UHFFFAOYSA-N 0.000 description 1
JRAPAWFDOQVLLC-QURGRASLSA-N 4-[(e)-4-hydroxy-1,2-diphenylbut-1-enyl]phenol Chemical compound C=1C=CC=CC=1C(/CCO)=C(C=1C=CC(O)=CC=1)\C1=CC=CC=C1 JRAPAWFDOQVLLC-QURGRASLSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 description 1
206010067572 Oestrogenic effect Diseases 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000001278 effect on cholesterol Effects 0.000 description 1
201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001030 gas--liquid chromatography Methods 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000026030 halogenation Effects 0.000 description 1
238000005658 halogenation reaction Methods 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000012606 in vitro cell culture Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000009245 menopause Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BG104713A 1998-02-19 2000-08-28 Е-2-[4-(4-хлоро-1,2-дифенил-бут-1-енил) фенокси]-етанол и негови фармацевтични състави BG64471B1 (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9803521.5A GB9803521D0 (en)	1998-02-19	1998-02-19	New compounds and pharmaceutical compositions thereof

Publications (2)

Publication Number	Publication Date
BG104713A BG104713A (bg)	2001-03-30
BG64471B1 true BG64471B1 (bg)	2005-04-30

Family

ID=10827263

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG104713A BG64471B1 (bg)	1998-02-19	2000-08-28	Е-2-[4-(4-хлоро-1,2-дифенил-бут-1-енил) фенокси]-етанол и негови фармацевтични състави

Country Status (33)

Country	Link
US (1)	US6395785B1 (sr)
EP (1)	EP1056701B1 (sr)
JP (1)	JP2002503713A (sr)
KR (1)	KR100755918B1 (sr)
CN (1)	CN1161314C (sr)
AR (1)	AR014961A1 (sr)
AT (1)	ATE252531T1 (sr)
AU (1)	AU755798B2 (sr)
BG (1)	BG64471B1 (sr)
BR (1)	BR9907688A (sr)
CA (1)	CA2321122C (sr)
CZ (1)	CZ294315B6 (sr)
DE (1)	DE69912247T2 (sr)
DK (1)	DK1056701T3 (sr)
EA (1)	EA002919B1 (sr)
EE (1)	EE04233B1 (sr)
ES (1)	ES2211038T3 (sr)
GB (1)	GB9803521D0 (sr)
GE (1)	GEP20022794B (sr)
HR (1)	HRP20000545A2 (sr)
HU (1)	HUP0101354A3 (sr)
ID (1)	ID26857A (sr)
IL (1)	IL137214A (sr)
NO (1)	NO325595B1 (sr)
NZ (1)	NZ505637A (sr)
PL (1)	PL193315B1 (sr)
PT (1)	PT1056701E (sr)
RS (1)	RS49660B (sr)
SK (1)	SK285940B6 (sr)
TR (1)	TR200002037T2 (sr)
UA (1)	UA57132C2 (sr)
WO (1)	WO1999042427A1 (sr)
ZA (1)	ZA991232B (sr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1705169A3 (en) *	1999-11-16	2006-11-15	Hormos Medical Ltd.	Triphenylalkene derivatives and their use as selective estrogen receptor modulators
TW593256B (en) *	1999-11-16	2004-06-21	Hormos Medical Oy Ltd	Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US20040248989A1 (en)	2003-06-05	2004-12-09	Risto Santti	Method for the treatment or prevention of lower urinary tract symptoms
JP5123935B2 (ja)	2006-05-22	2013-01-23	ホルモスメディカルリミテッド	選択的エストロゲン受容体モジュレーターまたはアロマターゼ阻害剤を用いた慢性非細菌性前立腺炎の治療方法
WO2008099060A2 (en) *	2007-02-14	2008-08-21	Hormos Medical Ltd	Methods for the preparation of fispemifene from ospemifene
ES2590262T3 (es)	2007-02-14	2016-11-21	Hormos Medical Ltd.	Método para la preparación de derivados de trifenilbuteno con valor terapéutico
RS53353B (sr)	2010-01-19	2014-10-31	Cambrex Karlskoga Ab	Novi postupci za proizvodnju derivata benzofenona
US9321712B2 (en)	2012-10-19	2016-04-26	Fermion Oy	Process for the preparation of ospemifene
US20150321983A1 (en) *	2012-10-19	2015-11-12	Fermion Oy	A process for the preparation of ospemifene
CN104030896A (zh) *	2013-03-07	2014-09-10	天津药物研究院	一种简易去除欧司哌米芬特异杂质的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997032574A1 (en) *	1996-03-04	1997-09-12	Orion-Yhtymä Oy	Serum cholesterol lowering agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2126576B (en)	1982-06-25	1985-06-19	Farmos Group Limited	Alkane and alkene derivatives
GB9418067D0 (en) *	1994-09-07	1994-10-26	Orion Yhtymae Oy	Triphenylethylenes for the prevention and treatment of osteoporosis

1998
- 1998-02-19 GB GBGB9803521.5A patent/GB9803521D0/en not_active Ceased
1999
- 1999-02-16 AR ARP990100642A patent/AR014961A1/es active IP Right Grant
- 1999-02-16 ZA ZA9901232A patent/ZA991232B/xx unknown
- 1999-02-19 US US09/601,612 patent/US6395785B1/en not_active Expired - Fee Related
- 1999-02-19 JP JP2000532381A patent/JP2002503713A/ja active Pending
- 1999-02-19 GE GEAP19995553A patent/GEP20022794B/en unknown
- 1999-02-19 KR KR1020007008982A patent/KR100755918B1/ko not_active Expired - Fee Related
- 1999-02-19 CZ CZ20002927A patent/CZ294315B6/cs not_active IP Right Cessation
- 1999-02-19 BR BR9907688-8A patent/BR9907688A/pt not_active Application Discontinuation
- 1999-02-19 TR TR2000/02037T patent/TR200002037T2/xx unknown
- 1999-02-19 CA CA002321122A patent/CA2321122C/en not_active Expired - Fee Related
- 1999-02-19 ID IDW20001841A patent/ID26857A/id unknown
- 1999-02-19 EP EP99904899A patent/EP1056701B1/en not_active Expired - Lifetime
- 1999-02-19 WO PCT/FI1999/000137 patent/WO1999042427A1/en not_active Ceased
- 1999-02-19 NZ NZ505637A patent/NZ505637A/xx unknown
- 1999-02-19 UA UA2000095331A patent/UA57132C2/uk unknown
- 1999-02-19 AU AU25244/99A patent/AU755798B2/en not_active Ceased
- 1999-02-19 DK DK99904899T patent/DK1056701T3/da active
- 1999-02-19 CN CNB998030139A patent/CN1161314C/zh not_active Expired - Fee Related
- 1999-02-19 RS YUP-510/00A patent/RS49660B/sr unknown
- 1999-02-19 ES ES99904899T patent/ES2211038T3/es not_active Expired - Lifetime
- 1999-02-19 HU HU0101354A patent/HUP0101354A3/hu unknown
- 1999-02-19 PL PL342445A patent/PL193315B1/pl unknown
- 1999-02-19 EE EEP200000473A patent/EE04233B1/xx not_active IP Right Cessation
- 1999-02-19 AT AT99904899T patent/ATE252531T1/de not_active IP Right Cessation
- 1999-02-19 EA EA200000851A patent/EA002919B1/ru not_active IP Right Cessation
- 1999-02-19 HR HR20000545A patent/HRP20000545A2/xx not_active Application Discontinuation
- 1999-02-19 IL IL13721499A patent/IL137214A/xx unknown
- 1999-02-19 SK SK1205-2000A patent/SK285940B6/sk unknown
- 1999-02-19 DE DE69912247T patent/DE69912247T2/de not_active Expired - Fee Related
- 1999-02-19 PT PT99904899T patent/PT1056701E/pt unknown
2000
- 2000-08-07 NO NO20003987A patent/NO325595B1/no unknown
- 2000-08-28 BG BG104713A patent/BG64471B1/bg unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997032574A1 (en) *	1996-03-04	1997-09-12	Orion-Yhtymä Oy	Serum cholesterol lowering agent

Also Published As

Publication number	Publication date
DE69912247T2 (de)	2004-07-29
NO20003987L (no)	2000-08-07
GEP20022794B (en)	2002-09-25
EE04233B1 (et)	2004-02-16
SK285940B6 (sk)	2007-11-02
CZ20002927A3 (cs)	2000-12-13
EP1056701B1 (en)	2003-10-22
HUP0101354A2 (hu)	2002-03-28
JP2002503713A (ja)	2002-02-05
YU51000A (sh)	2002-11-15
IL137214A (en)	2005-05-17
PL193315B1 (pl)	2007-01-31
UA57132C2 (uk)	2003-06-16
NO20003987D0 (no)	2000-08-07
NZ505637A (en)	2002-10-25
AU755798B2 (en)	2002-12-19
DE69912247D1 (de)	2003-11-27
IL137214A0 (en)	2001-07-24
AU2524499A (en)	1999-09-06
BG104713A (bg)	2001-03-30
ATE252531T1 (de)	2003-11-15
NO325595B1 (no)	2008-06-23
CA2321122C (en)	2008-02-12
EP1056701A1 (en)	2000-12-06
EA200000851A1 (ru)	2001-02-26
CN1291178A (zh)	2001-04-11
PT1056701E (pt)	2004-03-31
KR20010040985A (ko)	2001-05-15
RS49660B (sr)	2007-09-21
CN1161314C (zh)	2004-08-11
HRP20000545A2 (en)	2001-02-28
TR200002037T2 (tr)	2001-02-21
AR014961A1 (es)	2001-04-11
PL342445A1 (en)	2001-06-04
HUP0101354A3 (en)	2002-05-28
CZ294315B6 (cs)	2004-11-10
GB9803521D0 (en)	1998-04-15
DK1056701T3 (da)	2004-02-02
ID26857A (id)	2001-02-15
BR9907688A (pt)	2000-11-14
KR100755918B1 (ko)	2007-09-06
US6395785B1 (en)	2002-05-28
SK12052000A3 (sk)	2001-01-18
ZA991232B (en)	1999-09-17
EE200000473A (et)	2001-12-17
ES2211038T3 (es)	2004-07-01
WO1999042427A1 (en)	1999-08-26
EA002919B1 (ru)	2002-10-31
CA2321122A1 (en)	1999-08-26

Publication	Publication Date	Title
CN1332974C (zh)	2007-08-22	抗雌激素甾族化合物、有关的药学组合物和使用方法
EP0615448B1 (en)	2002-05-02	Sex steroid activity inhibitors
TW399036B (en)	2000-07-21	Naphthyl compounds, intermediates, pharmaceutical, compositions, and preparation process thereof
CN1181077A (zh)	1998-05-06	苯并吡喃类化合物及其使用方法
US5393785A (en)	1995-02-28	Therapeutic antiestrogens
EP0547179A1 (en)	1993-06-23	Triarylethylene carboxylic acids with estrogenic activity
JP4113583B2 (ja)	2008-07-09	血清コレステロール低下薬
JPH09511506A (ja)	1997-11-18	ステロイドホルモン及びその拮抗薬の永久的イオン性誘導体
AU755798B2 (en)	2002-12-19	E-2-{4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy}ethanol and pharmaceutical compositions thereof
US9315539B2 (en)	2016-04-19	11 beta-short chain substituted estradiol analogs and their use in the treatment of menopausal symptoms and estrogen sensitive cancer
EP0778025B1 (en)	2004-04-07	Use of 8,9-dehydroestrone for the manufacture of a medicament for the treatment of diseases caused by free radicals
EP0850647B1 (fr)	2003-03-26	Application de composés stéroides substitués en ll pour la fabrication de médicaments ayant une activité estrogène dissociée
WO1998028324A9 (fr)	1998-10-29	Steroides substitues en position 11, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
ZA200408116B (en)	2007-04-25	5-{2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino}-phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy
MXPA00008134A (es)	2002-05-09	E-2-[4-(4-cloro-1,2-difenil-but-1-enil)fenoxi]etanol y composiciones farmaceuticas del mismo
JPS59157023A (ja)	1984-09-06	エストロジエン欠乏状態の治療方法
HK1010095B (en)	2005-01-14	Use of 8, 9-dehydroestrone for the manufacture of a medicament for the treatment of diseases caused by free radicals